Trials / Recruiting
RecruitingNCT06066333
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Safety and Immunological Effects of Pembrolizumab Plus Ablative Radiotherapy in Patients With Advanced Adrenocortical Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Ablative Radiotherapy | All participants will first undergo ablative RT |
| DRUG | Pembrolizumab | After completion of ablative RT, all subjects may begin pembrolizumab treatment |
Timeline
- Start date
- 2023-09-27
- Primary completion
- 2026-09-27
- Completion
- 2026-09-27
- First posted
- 2023-10-04
- Last updated
- 2026-04-15
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06066333. Inclusion in this directory is not an endorsement.